Sl-401

Sl-401 Reactions 1704, p345 - 2 Jun 2018 Various toxicities: 2 case reports In a retrospective study, a 10-year-old girl developed facial flushing, fever, tachycardia, hypoxia and urgency to evacuate bowel, and a 15-year-old girl developed pyrexia, hypoxia, shortness of breath, hypoalbuminaemia, mild peripheral oedema, weight gain and capillary leak syndrome (CLS) following treatment with SL-401 for blastic plasmacytoid dendritic cell neoplasm (BPDCN) [time to reaction onset and not all outcomes stated]. Case 1: The 10-year-old girl, who was diagnosed with BPDCN, started receiving treatment with SL-401 12 µg/kg/day infusion every 2–3 weeks. During first course, she developed facial flushing and fever, which resulted in a 24 hours delay of the third dose. At the end of first course, she had stable scalp lesions and 0.33% bone marrow (BM) minimal residual disease (MRD). During second course, she developed tachycardia, hypoxia and urgency to evacuate bowel shortly following the second dose. The symptoms improved quickly after oxygen and diphenhydramine. Later, she tolerated subsequent doses with premedication. End of second course BM showed 80% blast. Blasts from both scalp lesion and BM remained to be CD123 positive. Treatment with SL-401 was discontinued. She died 5 months following progressive disease. Case 2: The 15-year-old girl, who was diagnosed with BPDCN started receiving treatment with SL-401 12 µg/kg/day infusion every 2–3 weeks. During first course, she experienced pyrexia, hypoxia and shortness of breath, which recovered following diphenhydramine. At the end of first course, she had a partial response with the disappearance of the peripheral blast. During second course, she again experienced transient fever and mild peripheral oedema. The fifth dose was held due to a 5kg weight gain and hypoalbuminaemia. The development of hypoalbuminaemia and weight gain, suggested possible development of CLS. Later, SL-401 treatment was discontinued. Due to progressive disease and she died after few months. Author comment: "Here, we report the first pediatric experience with SL-401. Similar to adults, we observed mild, transient infusion-related AEs that were easily manageable." Sun W, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: Report of three cases. Journal of Hematology and Oncology 11: 61, No. 1, 2 May 2018. Available from: URL: http://doi.org/10.1186/s13045-018-0604-6 - USA 803323590 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Sl-401

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/sl-401-CariSOW4v2
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46988-y
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p345 - 2 Jun 2018 Various toxicities: 2 case reports In a retrospective study, a 10-year-old girl developed facial flushing, fever, tachycardia, hypoxia and urgency to evacuate bowel, and a 15-year-old girl developed pyrexia, hypoxia, shortness of breath, hypoalbuminaemia, mild peripheral oedema, weight gain and capillary leak syndrome (CLS) following treatment with SL-401 for blastic plasmacytoid dendritic cell neoplasm (BPDCN) [time to reaction onset and not all outcomes stated]. Case 1: The 10-year-old girl, who was diagnosed with BPDCN, started receiving treatment with SL-401 12 µg/kg/day infusion every 2–3 weeks. During first course, she developed facial flushing and fever, which resulted in a 24 hours delay of the third dose. At the end of first course, she had stable scalp lesions and 0.33% bone marrow (BM) minimal residual disease (MRD). During second course, she developed tachycardia, hypoxia and urgency to evacuate bowel shortly following the second dose. The symptoms improved quickly after oxygen and diphenhydramine. Later, she tolerated subsequent doses with premedication. End of second course BM showed 80% blast. Blasts from both scalp lesion and BM remained to be CD123 positive. Treatment with SL-401 was discontinued. She died 5 months following progressive disease. Case 2: The 15-year-old girl, who was diagnosed with BPDCN started receiving treatment with SL-401 12 µg/kg/day infusion every 2–3 weeks. During first course, she experienced pyrexia, hypoxia and shortness of breath, which recovered following diphenhydramine. At the end of first course, she had a partial response with the disappearance of the peripheral blast. During second course, she again experienced transient fever and mild peripheral oedema. The fifth dose was held due to a 5kg weight gain and hypoalbuminaemia. The development of hypoalbuminaemia and weight gain, suggested possible development of CLS. Later, SL-401 treatment was discontinued. Due to progressive disease and she died after few months. Author comment: "Here, we report the first pediatric experience with SL-401. Similar to adults, we observed mild, transient infusion-related AEs that were easily manageable." Sun W, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: Report of three cases. Journal of Hematology and Oncology 11: 61, No. 1, 2 May 2018. Available from: URL: http://doi.org/10.1186/s13045-018-0604-6 - USA 803323590 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off